Login / Signup

Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.

Shogo KobayashiHideki SanoKazuhiro MochizukiYoshihiro OharaNobuhisa TakahashiHitoshi OhtoAtsushi Kikuta
Published in: Pediatrics international : official journal of the Japan Pediatric Society (2018)
Pre-emptive rituximab therapy could be a useful strategy for EBV-PTLD in TCR-haplo-SCT recipients with low-dose ATG.
Keyphrases
  • epstein barr virus
  • diffuse large b cell lymphoma
  • low dose
  • regulatory t cells
  • high dose
  • acute myeloid leukemia
  • hodgkin lymphoma
  • kidney transplantation
  • immune response
  • dendritic cells
  • mesenchymal stem cells